
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health Inc demonstrated robust financial performance with a 6.3% increase in gross margin dollar generation during the quarter, indicating effective cost management and operational efficiency. The company's commitment to shareholder value was evidenced by a significant stock repurchase program, which increased from previous quarters, alongside a 10% growth in its chronic therapy business. Additionally, Option Care Health's enhanced financial guidance for FY/25, coupled with strong cash flow generation and the potential for improved margins through increased utilization, positions the company favorably for sustained revenue growth.
Bears say
Option Care Health Inc. faces a negative outlook primarily due to rising general and administrative (G&A) expenses as a percentage of revenue, which is expected to decline only gradually over several quarters. The company currently relies heavily on its largest customer, which constitutes 14% of its revenue, making it vulnerable to significant financial impacts in the event of a customer loss. Additionally, anticipated gross profit headwinds related to the Stelara product and its biosimilars are projected to reach between $25 million to $35 million, likely limiting both EBITDA margin expansion and overall profitability in the near term.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares